Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
Retrieved on:
Tuesday, December 6, 2022
National University of Singapore, Applied science, Biocatalysis, Interdisciplinarity, Agency, Disease, Associate, Biology, SIT, Assistant, EDB, D, Robotics, National university, Partnership, Carbon, GSK, Sustainability, Learning, Ecosystem, 2025, NUS, Science and Engineering Research Council, Vaccine, Environment, Agency for Science, Technology and Research, COVID-19, Innovation, Machine learning, Shannon Applied Biotechnology Centre, Biomedicine, Enablement, NTU, Singapore Institute of Technology, Nanyang Technological University, Pandemic, Committee on the Office of the Deputy Prime Minister, PIPS, Analytics, A*STAR, Biomedical Research Council, Framework Programmes for Research and Technological Development, Pharmaceutical industry, Management, Fine chemical, Sanofi, Research, Science, Takeda
BioPIPS seeks to use research and innovation to grow Singapore's manufacturing capabilities for biologics, which include recombinant therapeutic proteins, and vaccines.
Key Points:
- BioPIPS seeks to use research and innovation to grow Singapore's manufacturing capabilities for biologics, which include recombinant therapeutic proteins, and vaccines.
- Amid the COVID-19 pandemic, biologics and vaccines played a critical role globally in preventing severe disease and saving lives.
- The consortium ultimately aims to make Singapore's biologics manufacturing capabilities best-in-class and well-positioned for the introduction of new products and novel manufacturing technologies.
- "Riding on the success of PIPS, BioPIPS aims to enhance Singapore's innovation capabilities in biologics and vaccines manufacturing by leveraging the strengths of our leading pharmaceutical companies and institutes of higher learning.